Jolanta Siller-Matula

Summary

Affiliation: Medical University of Vienna
Location: Vienna, Austria

Publications

  1. ncbi Ticagrelor: from discovery to Phase III clinical trial
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Future Cardiol 6:753-64. 2010
  2. ncbi Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    Evid Based Med 16:144-5. 2011
  3. ncbi An experimental model to study isolated effects of thrombin in vivo
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 126:454-61. 2010
  4. ncbi Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Heart 97:98-105. 2011
  5. ncbi Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Clin Res Cardiol 99:645-50. 2010
  6. ncbi Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Pharmacol 159:502-17. 2010
  7. ncbi Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, and 5th Medical Department, Kaiser Franz Josef Hospital, Vienna, Austria
    J Thromb Haemost 8:351-9. 2010
  8. ncbi Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
    Thromb Haemost 102:397-403. 2009
  9. ncbi The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:874-80. 2009
  10. ncbi Thienopyridines in cardiovascular disease: focus on clopidogrel resistance
    Jolanta Siller-Matula
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A 1160 Vienna, Austria
    Thromb Haemost 97:385-93. 2007

Detail Information

Publications19

  1. ncbi Ticagrelor: from discovery to Phase III clinical trial
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Future Cardiol 6:753-64. 2010
    ..However, ticagrelor did not only reduce death due to vascular causes but also all-cause mortality. Further clinical trials in indications other than acute coronary syndrome are awaited...
  2. ncbi Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    Evid Based Med 16:144-5. 2011
  3. ncbi An experimental model to study isolated effects of thrombin in vivo
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 126:454-61. 2010
    ..We hypothesized that protracted intravenous infusion of thrombin at steady state will allow to study isolated thrombin effects in vivo...
  4. ncbi Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Heart 97:98-105. 2011
    ..Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding...
  5. ncbi Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Clin Res Cardiol 99:645-50. 2010
    ..The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS(®) stent with sirolimus-eluting CYPHER(®) stent for the prevention of symptom-driven clinical end points in a real world clinical setting...
  6. ncbi Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Pharmacol 159:502-17. 2010
    ..Whether these potential advantages will translate into clinical advantages will require additional comparisons in properly powered, randomized, controlled trials...
  7. ncbi Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, and 5th Medical Department, Kaiser Franz Josef Hospital, Vienna, Austria
    J Thromb Haemost 8:351-9. 2010
    ..As no direct comparison between the two methods has been made so far, we investigated which laboratory approach has a better predictive value for stent thrombosis...
  8. ncbi Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
    Thromb Haemost 102:397-403. 2009
    ..Maximal effects were seen 2 hours after aspirin loading and shorter than 72 hours after clopidogrel loading. In conclusion, aspirin and clopidogrel produce stronger signals in the MEA compared to several other methods...
  9. ncbi The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:874-80. 2009
    ..The aim was to investigate if the inhibition of platelet function by clopidogrel and aspirin is equal at two different time points: immediately after percutaneous coronary intervention (PCI) and one day thereafter...
  10. ncbi Thienopyridines in cardiovascular disease: focus on clopidogrel resistance
    Jolanta Siller-Matula
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A 1160 Vienna, Austria
    Thromb Haemost 97:385-93. 2007
    ..Prasugrel is one of the incoming new drugs with high expectations, but other agents might follow in the near future...
  11. ncbi Interspecies differences in coagulation profile
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 100:397-404. 2008
    ..Moreover, our findings confirm the potential usefulness of pigs as an experimental species to study fibrinolytic pathway and support the usefulness of rabbits as a species for examining platelets...
  12. ncbi Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Food Chem Toxicol 46:3550-2. 2008
    ..This indicates that the Wistar rats were more sensitive to a 5 h anaesthesia with isoflurane after a premedication with ketamin/xylazine in the described study design...
  13. ncbi Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Platelets 19:551-4. 2008
    ..This variability can be easily avoided to facilitate comparison of data between different laboratories...
  14. ncbi Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Am Coll Cardiol 52:1557-63. 2008
    ..Because of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized that there might be a drug-drug interaction between clopidogrel and dihydropyridines in patients with coronary artery disease...
  15. ncbi Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Am Heart J 157:148.e1-5. 2009
    ..As proton pump inhibitors are metabolized to varying degrees by CYP2C19, we hypothesized that the reported negative omeprazole-clopidogrel drug interaction may not be a class effect...
  16. ncbi Continuous thrombin infusion leads to a bleeding phenotype in sheep
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Thromb Res 130:226-36. 2012
    ..In addition to a recognized role in the coagulation cascade and haemostasis, thrombin is known to have multiple functions. We aimed to establish an ovine model to study thrombin effects in vivo...
  17. ncbi Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
    J M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 10:529-42. 2012
    ..Prognostic values of genotyping and phenotyping for assessment of clopidogrel responsiveness have been shown in independent studies...
  18. ncbi Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 106:1020-33. 2011
    ....